Skip to main content

Table 2 Multivariate analysis of propensity score–weighted population with breast cancer and heart failure with reduced ejection fraction receiving total mastectomy

From: Adjuvant postmastectomy radiotherapy might be associated with better survival in women with heart failure receiving total mastectomy

 

Death

Local recurrence

Distant metastasis

aHR*

(95% CI)

P value

aHR*

(95% CI)

P value

aHR*

(95% CI)

p value

Adjuvant RT

 No

Ref

 

0.0003

Ref

 

0.0356

Ref

 

0.6854

 Yes

0.52

(0.37–0.74)

 

0.90

(0.79–0.96)

 

0.89

(0.54–1.50)

 

Age

 20–69

Ref

 

0.0020

Ref

 

0.1200

Ref

 

0.2901

 70+

1.63

(1.20–2.22)

 

1.29

(0.81–2.49)

 

0.75

(0.44–1.28)

 

Diagnosis year

 2009–2012

Ref

 

0.3507

Ref

 

0.2770

Ref

 

0.7421

 2013–2016

0.79

(0.69–1.31)

 

0.73

(0.58–1.21)

 

0.81

(0.57–1.75)

 

CCI scores

 0

Ref

 

0.0322

Ref

 

0.1434

Ref

 

0.2112

 1

1.26

(1.14–1.97)

 

1.21

(0.92–1.79)

 

1.35

(0.85–1.97)

 

Differentiation

 I

Ref

 

0.0177

Ref

 

0.0146

Ref

 

0.0046

 II

1.09

(1.01–1.60)

 

1.36

(1.02–3.59)

 

1.36

(1.02–3.59)

 

 III

1.47

(1.09–2.40)

 

1.37

(1.11–3.71)

 

1.37

(1.01–3.71)

 

pT

 pT1

Ref

 

< 0.0001

Ref

 

0.0016

Ref

 

0.0196

 pT2

1.38

(1.07–1.97)

 

1.35

(1.05–3.12)

 

1.09

(1.04–3.04)

 

 pT3–4

2.91

(1.90–4.44)

 

2.62

(1.19–4.72)

 

2.35

(1.13–4.89)

 

pN

 pN0

Ref

 

< 0.0001

Ref

 

0.0040

Ref

 

0.0082

 pN1

1.94

(1.38–2.72)

 

1.09

(1.03–1.41)

 

2.38

(1.37–4.12)

 

 pN2–3

2.90

(2.01–4.18)

 

1.26

(1.06–1.37)

 

1.88

(1.01–3.51)

 

Hypertension

1.08

(0.77–1.81)

0.4882

0.90

(0.59–1.56)

0.7217

0.95

(0.69–1.48)

0.8021

CAD

1.11

(0.71–1.92)

0.3427

0.84

(0.53–1.39)

0.6914

0.94

(0.78–1.59)

0.3426

Diabetes

1.11

(0.73–1.90)

0.3422

1.01

(0.70–1.51)

0.4521

0.90

(0.55–1.91)

0.8909

Hormone receptor positive

0.87

(0.80–0.91)

0.0312

0.77

(0.45–0.82)

0.0204

0.72

(0.63–0.97)

0.0322

Trastuzumab use

1.07

(0.87–1.42)

0.34661

1.09

(0.58–2.01)

0.3831

1.06

(0.81–1.54)

0.3421

Anthracycline-based chemotherapy

0.94

(0.57–1.88)

0.4065

0.93

(0.78–1.83)

0.2412

0.84

(0.70–2.20)

0.1683

Nodal surgery

 ALND

Ref

 

0.3322

Ref

 

0.2434

Ref

 

0.2112

 SLNB

1.06

(0.54–1.09)

 

1.01

(0.82–1.79)

 

1.15

(0.85–2.97)

 

Hospital level

 Academic center

Ref

 

0.2177

Ref

 

0.2177

Ref

 

0.8146

 Nonacademic center

0.99

(0.61–1.60)

 

0.99

(0.61–1.60)

 

1.36

(0.52–3.59)

 
  1. aHR adjusted hazard ratios, CIs confidence intervals, HR hormone receptor, Her-2 human epidermal growth factor receptor-2, CCI Charlson comorbidity index, T tumor, N nodal, pT pathologic tumor stage, pN pathologic nodal stage, ALND axillary lymph node dissection, SNLB sentinel lymph node biopsy, ref reference group, RT radiotherapy
  2. *All covariates mentioned in Table were adjusted